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Acute Liver Failure Due To Amoxicillin and
Amoxicillin/Clavulanate
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The aim of our study is to report upon the presentation of two patients with life-threatening acute
liver failure (ALF) due to amoxicillin and amoxicillin/clavulanate. A 59-year-old, Caucasian male
presented with ALF 34 days after receiving amoxicillin/clavulanate. Despite aggressive supportive
care, he died on hospital day 10. A 42-year-old, Caucasian female presented with ALF 21 days after
receiving amoxicillin. She underwent successful liver transplantation on hospital day 19. In both
cases, all competing causes of ALF had been excluded, liver pathology was consistent with drug-
induced hepatitis, and cases were deemed “definite/highly probable” using causality assessment.
Amongst 14 prior ALF/death cases due to amoxicillin/clavulanate, the mean age (62 years), male
predominance (57%), and mean delay from drug cessation to presentation (17 days) is similar to
what has been reported in patients with self-limited cholestatic hepatitis. Acute liver failure is a rare
manifestation of amoxicillin and amoxicillin/clavulanate hepatotoxicity with no obvious clinical
features at presentation portending a poor prognosis. Early transfer of patients with severe drug-
induced hepatotoxicity (i.e., encephalopathy or coagulopathy) to a transplant center is recommended
due to their poor likelihood of recovery.
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Ampicillin and amoxicillin are commonly used semisyn-
thetic penicillins that are associated with a very low rate
of mild hepatocellular and cholestatic liver injury when
used alone (1, 2). However, when amoxicillin is com-
bined with the B-lactamase inhibitor, clavulanic acid or
clavulanate (Augmentin, GlaxoSmithKline, Research
Triangle Park, NC), the estimated risk of hepatotoxicity in-
creases from 3 to 17 per 100,000 prescriptions presumably
due to the clavulanate component (2). Men over the age of
50 appear to be at increased risk of amoxicillin/clavulanate
hepatotoxicity as are patients who receive prolonged or re-
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peated courses of treatment (2). A delayed cholestatic or
mixed hepatocellular-cholestatic liver injury pattern has
typically been reported with amoxicillin/clavulanate that
usually has a benign course and resolves within 2 months
(2–5).
Acute liver failure (ALF) is a rare but devastating illness
defined as the onset of coagulopathy and encephalopa-
thy within 8 weeks of presentation in a patient without
known underlying liver disease (6). Although a multi-
tude of causes of ALF have been identified, a prospec-
tive study of 309 consecutive ALF patients demonstrated
that acetaminophen (33%) and idiosyncratic drug-induced
hepatotoxicity (13%) were the most commonly identified
causes of ALF in the United States (7). Although most pa-
tients with amoxicillin and amoxicillin/clavulanate hepa-
totoxicity recover with supportive care, we recently ob-
served two patients with life-threatening ALF because of
these medications. The aim of this study is to report on
the presentation and clinical course of two patients with
ALF due to amoxicillin and amoxicillin/clavulanate. We
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also set out to identify potential features associated with
severe outcomes by reviewing the published literature.
METHODS
The United States Acute Liver Failure Study Group (ALFSG)
is a consortium of 24 referral centers studying the etiologies,
natural history, and outcomes of patients with ALF. Between
January 1998 and August 2003, 610 consecutive ALF patients
were enrolled into a 3-week observational study including 76 pa-
tients with idiosyncratic drug-induced hepatotoxicity. Etiologi-
cal diagnoses were made at each study center using accepted di-
agnostic criteria (7). Laboratory, clinical, and outcome data were
collected from all participants at death, liver transplantation, or
3 weeks of follow-up. The research protocol was reviewed and
approved by the Institutional Review Board of the participating
institutions and written informed consent was obtained from the
next of kin of all participants. A Certificate of Confidentiality
was obtained for the entire study.
Causality Assessment
To standardize the diagnostic criteria for drug-induced liver
injury, several scoring systems have been proposed (8, 9). The
Council for International Organization of Medical Sciences
(CIOMS) scale uses seven clinical criteria to generate a score
that varies between −5 and +14 and is categorized into five
levels of causality : >8 definite/highly probable, 6–8 probable,
3–5 possible, 1–2 unlikely, and ≤0 excluded. The CIOMS score
has been validated by applying data from a large number of pa-
tients who had been rechallenged with the suspect agent (10, 11).
The Clinical Diagnostic Scale (CDS) provides a score between
6 and 20 that can be categorized into 4 levels of causality: >17
definite, 14–16 probable, 10–13 possible, and 6–9 unlikely. The
CDS was validated using cohorts of real cases, fictitious cases,
and the opinions of an external expert panel (12, 13).
RESULTS
Case #1
A 59-year old, Caucasian male presented to his pri-
mary care physician with cough and fatigue in early
June ‘03. The patient had a history of hyperten-
sion treated with atenolol 100 mg per day and tri-
amterene/hydrochlorothiazide 75/50 mg per day for the
past year. Hyperlipidemia was treated with atorvastatin
20 mg per day for 5 years and the patient also received
monthly testosterone injections (400 mg for 5 years) and
sildenafil 25 mg as needed for impotence. The patient re-
ported taking hydrocodone/acetaminophen 5/500 mg and
naproxen 500 mg once a day as needed for osteoarthritis
of the knee. He had no known drug allergies. On 6/6/03,
amoxicillin/clavulanate 500/125 mg twice a day was pre-
scribed for scalp cellulitis which he took for 12 days.
On 6/25/03, routine labs revealed an AST 107 IU/L, ALT
141 IU/L, alkaline phosphatase 98 IU/L, INR 1.0 and nor-
mal total bilirubin. In evaluating his abnormal serum
aminotransferase levels, hepatitis A, B, C, epstein-barr
virus, cytomegalovirus, anti-nuclear (ANA) and smooth
muscle antibodies were all negative or undetectable. In
addition, serum ceruloplasmin, alpha-1 anti-trypsin, and
iron levels were normal as was a liver ultrasound. Because
of persistent scalp erythema, he was prescribed amoxi-
cillin alone 500 mg three times a day on 7/5/03 which he
took for 3 days.
On 7/22/03 he was hospitalized with generalized
malaise, vomiting, and jaundice. On physical examina-
tion, there were was a scaly rash involving the scalp and
legs but no evidence of ascites or stigmata of chronic liver
disease. The patient denied a history of recent alcohol in-
gestion, illicit drug use, travel, or consumption of over the
counter or herbal products. His admission serum ALT was
620 IU/L, AST 628 IU/L, alkaline phosphatase 170 IU/L
and bilirubin 27.6 mg/dL with INR 2.0. His admission
WBC was 12,600 cells/mL with no eosinophils. The ANA,
smooth muscle antibody, and anti-mitochondrial antibod-
ies were negative and HCV RNA and HBV DNA were
undetectable. Over the next 3 days, the patient developed
worsening hepatic encephalopathy and coagulopathy con-
sistent with ALF. A transjugular liver biopsy on hospital
day # 6 revealed acute hepatitis with confluent necrosis
predominating in the central zones consistent with a drug
reaction (Figure 1). Because of his worsening liver func-
tion, he was placed on the liver transplant waiting list on
hospital day #8. Despite antibiotics and supportive care, he
developed respiratory failure and refractory hypotension
necessitating intubation, pressors, and continuous venove-
nous hemofiltration and he died 2 days later of multiorgan
failure. Permission for an autopsy was denied.
Case #2
A 42-year old Caucasian female presented on 2/20/01
with a 4-week history of malaise and jaundice. The pa-
tient had received hydrocodone/ibuprofen 7.5/200 mg per
day and amoxicillin 500 mg three times a day for 6 days
in late January 2001 following dental work for an in-
fected tooth. At admission to the outside hospital on
2/20/01, serum AST was 1189 IU/mL, ALT 521 IU/mL,
gammaglutamyl transpeptidase (GGTP) 89 IU/mL, and
bilirubin 23.0 mg/dL with INR of 1.4 The WBC was
6000 cells/mL with no eosinophilia. The patient was
deeply jaundiced but there was no rash, adenopathy, as-
cites, or stigmata of chronic liver disease. She denied a
history of drug allergies, alcohol use, illicit drug use, re-
cent travel, or prior medical history. Laboratory evalua-
tion included negative serologies for hepatitis A, B, C,
ANA, and anti-smooth muscle antibody. Serum cerulo-
plasmin was normal. She was subsequently transferred
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Fig 1. Liver histology from patient #1 (A) and patient #2 (B). A). This low power photomicrograph shows
central zone necrosis (upper left) with neocholangiogenesis and mild portal inflammation B). This high-power
photomicrograph shows portal infiltrates of lymphocytes and eosinophils. Adjacent hepatocytes show ballooning
degeneration and cholestasis.
to the University of Pittsburgh Medical Center for fur-
ther evaluation on 2/22/01. An ultrasound guided liver
biopsy on hospital day #4 revealed expansion of the por-
tal tracts with a lymphoplasmacytic infiltrate, eosinophils
and mild ductular proliferation suggestive of a drug re-
action. Over the ensuing 10 days, she developed progres-
sive hepatic encephalopathy requiring intubation and was
listed for a liver transplant on hospital day #18 for drug-
induced ALF. At listing, her serum ALT was 766 IU/L,
AST 2075 IU/L, alkaline phosphatase 135 IU/mL, and
bilirubin 26.9 mg/dL with INR 2.0. An orthotopic liver
transplant was performed on hospital day #19. The patient
was discharged home on hospital day # 38 in stable con-
dition and is alive and well as of 9/04. Her explanted liver
weighed 1650 g and showed submassive hepatic necro-
sis. There were numerous areas of confluent central zone
necrosis with collapse and neocholangiogenesis consis-
tent with a drug reaction (Figure 1).
Causality Assessment
Patient #1 had a CIOMS score of 9 which is “defi-
nite/highly probable” and a CDS score of 13 which is
“possible” (Table 1). Similarly, patient #2 had a CIOMS
score of 9 which is “definite/highly probable” and a CDS
score of 9 which is “unlikely.”
DISCUSSION
We present two patients who developed life threat-
ening ALF associated with a short course of amoxi-
cillin/clavulanate and amoxicillin, respectively. The dose
and duration of antibiotics were within the labeling indica-
tions and neither of the patients had a history of known al-
lergy or intolerance to B-lactam antibiotics, alcohol use, il-
licit drug use, or prior liver disease. A thorough evaluation
for competing causes of liver injury was negative in both
instances. The development of hepatitis 4–6 weeks after
drug ingestion in both cases is consistent with prior reports
of B-lactam associated hepatotoxicity (2, 3). Neither pa-
tient had prominent features of a hypersensitivity reaction
such as fever and eosinophilia that has been reported in
up to 50% of patients with amoxicillin/clavulanate hepa-
totoxicity (4, 5). However, review of available liver histol-
ogy demonstrated histological features compatible with a
severe drug induced hepatitis in both cases (Figure 1).
Establishing a diagnosis of drug induced liver injury
requires a careful exclusion of competing causes and an
awareness of the hepatotoxicity profile of the suspect
agent. Both amoxicillin and amoxicillin/clavulanate are
widely prescribed antibiotics with an estimated 34 million
and 15 million prescriptions dispensed in the United States
alone in 2002, respectively (14). There have been multiple
TABLE 1. CIOMS AND CDS SCORES OF CASE PATIENTS
Case 1 Case 2
CIOMS
1. Time to onset +3 +3
2. Course of reaction +2 +2
3. Risk factor for drug reaction +1 0
4. Concomitant drugs −1 0
5. Nondrug-related causes +2 +2
6. Previous information on drug +2 +2
7. Response to readministration 0 0
Total Score +9 +9
Clinical Diagnostic Scale (CDS)
1. Temporal relationship
a. Time to onset +3 +3
b. Time from withdrawal +3 0
c. Time to normalize 0 0
2. Nondrug-related causes +3 +3
3. Extrahepatic manifestations +2 +1
4. Response to readministration 0 0
5. Previous information on drug +2 +2
Total Score +13 +9
Digestive Diseases and Sciences, Vol. 50, No. 10 (October 2005) 1787
FONTANA ET AL.
published reports of amoxicillin/clavulanate associated
cholesatic hepatitis since its introduction in the early 1980s
(2–6). A recent literature review indicates a male pre-
dominance (70%) with a mean age of onset of 60 years
(range: 1–90) (15). The mean delay between drug ex-
posure and presentation is 4 weeks with a range of 1–
8 weeks which can lead to a delay in diagnosis. The clin-
ical presentation of patient #1 is consistent with amox-
icillin/clavulanate hepatotoxicity since all other known
causes of ALF had been excluded and the patient was an el-
derly male who received a prolonged course of antibiotic
treatment. Although the patient was receiving other po-
tentially hepatotoxic medications (i.e., testosterone, ator-
vastatin, naproxen), these medications had been used for
prolonged periods of time and the temporal relationship
between amoxicillin/clavulanate use was most compati-
ble with a drug reaction. As previously mentioned, amox-
icillin alone is rarely identified as a cause of liver injury yet
alone ALF making causality assessment in case #2 more
challenging (1). However, this individual was previously
healthy and the absence of other identifiable etiologies in-
cluding other hepatotoxic medications and the timing of
her presentation after taking amoxicillin with liver histol-
ogy highly suggestive of an acute drug induced hepatitis
strongly support a diagnosis of amoxicillin-induced ALF.
To improve diagnostic accuracy, causality assessment
instruments have been proposed for patients with sus-
pected drug-induced liver injury (8, 9). Since there is no
“gold standard” laboratory or diagnostic test, these in-
struments are usually validated by comparing results to
that of an experienced expert panel. In this report, for-
mal causality assessment supported a diagnosis of drug
induced liver injury in both cases using the CIOMS in-
strument (Table 1). Although case #2 was scored as “un-
likely” using the CDS scale, it has previously been shown
that the CDS scale is most useful in patients with an acute
immunoallergic illness and less helpful in patients with
metabolic idiosyncrasy or a delayed presentation (13). In
addition, the CDS scale is not useful in assessing causality
in patients with ALF or fatal hepatotoxicity as was seen
in these two patients (13). These cases demonstrate the
limitations of the currently available causality assessment
instruments and the need to develop more accurate and
sensitive instruments.
The natural history of amoxicillin/clavulanate hepa-
totoxicity has been characterized as generally mild and
nearly always self-limited (3, 4). A systematic review of
208 cases demonstrated that normalization of liver bio-
chemistries occurred after a mean of 11.5 weeks (14).
Rare instances of chronic liver injury with ductopenia
and prolonged cholestasis have been reported (3, 4).
With an estimated incidence of 17 per 100,000 pre-
scriptions and 14 million Americans receiving amoxi-
cillin/clavulanate each year, one may anticipate up to
2400 cases of cholestatic hepatitis associated with this
agent each year. The two patients in the present report
represented 0.3% (2 of 610) of the ALF cases observed
during the study period by the US ALFSG. Since the cen-
ters participating in the US ALFSG account for ∼30% of
the liver transplant activity and capture 100 of the 2000
annual ALF cases in the United States, one would ex-
pect a maximum of six ALF cases due to amoxicillin and
amoxicillin/clavulanate in the United States on an annual
basis. These estimates combined with the large number
of patients taking these drugs on a daily basis suggest
that life-threatening hepatotoxicity due to amoxicillin and
amoxicillin/clavulanate is indeed rare.
A MEDLINE search using the keywords amoxicillin
and amoxicillin/clavulanate crossed with liver transplan-
tation, acute liver failure, toxic hepatitis, and death identi-
fied only six published articles describing 14 fatalities in
patients receiving amoxicillin/clavulanate and none due
to amoxicillin alone (16–22) (Table 2). Several of the
patients had prominent extrahepatic manifestations such
as Steven’s Johnson Syndrome, interstitial nephritis, and
thrombotic thrombocytopenic purpura emphasizing the
complex, systemic nature of some of these severe drug
reactions (16, 18, 22). In 1996, the Australian Adverse
Drug Reactions Advisory Committee (ADRAC) reported
nine Australian patients with amoxicillin/clavulanate hep-
atotoxicity that had died (21). However, in two of the
cases the cause of death was not felt to be drug-related
and in two others the primary cause of death was not
liver related while the remaining five died of liver fail-
ure. As of October 2003, the ADARC had recorded 18
fatal cases of amoxicillin/clavulanate in its registry (Ian
Boyd personal communication, February 2004). Review
of the published cases along with ours demonstrates that
there is a male predominance (57%) and the mean sub-
ject age is 62 years (range: 27–91) amongst ALF/fatal
cases. In addition, the mean time from completing amoxi-
cillin/clavulante to presentation was 17 days (range: 0–34)
which is similar to that of patients with self-limited amox-
icillin/clavulanate cholestatic hepatitis. Therefore, there
does not appear to be any obvious clinical risk factors for
severe outcomes versus self-limited hepatotoxicity from
amoxicillin/clavulanate and one may anticipate that ALF
will continue to be an exceedingly rare and unpredictable
manifestation of amoxicillin/clavulanate hepatotoxicity.
It is estimated that ∼10% of patients who develop jaun-
dice due to severe drug induced liver injury will die and
that elderly patients are more susceptible to drug induced
liver injury as well as poor outcomes (23, 24). Recent stud-
ies also suggest that patients with ALF due to idiosyncratic
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TABLE 2. ACUTE LIVER FAILURE AND MORTALITY REPORTED WITH AMOXICILLIN/CLAVULANATE
Series (ref #) Indication (days) Delay (d)* Age/sex Ethnicity Outcome
Australia (19, 21) Respiratory (28) 21 37 F NA Death—Liver related. Also received
valproate.
Bronchitis (2) 0 61 F NA Death—Liver related
NA NA NA F NA Death—Liver related
Urinary (10) 33 69 F NA Death—Liver related
Respiratory (10) 3 60 M NA Death—Heart failure and pulmonary
embolism
Respiratory(NA) NA 88 M NA Death—Pneumonia with severe
cholestasis
Urinary (28) 7 81 M C Death—Received ethinyl estradiol
and biopsy had cholestasis, died in
9 weeks
Turkey (18) Bronchitis (5) 1 40 F C Survived—Discharged on day 23
Pharyngitis (5) 1 66 M C Death—Thrombotic
thrombocytopenic purpura &
hemolytic anemia refractory to
steroids
United States (16) Pneumonia (10) 32 38 M C Death—Interstitial nephritis and
Stevens-Johnson refractory to
steroids, died in 10 weeks
United States (22) Pneumonia (4) 28 37 M C Death—Toxic epidermal necrolysis
present, died of multiorgan failure
at 3 months
Scotland (20) NA NA 91 F C Death—Recent hip surgery with
resolving cholestasis
Spain (17) Dental (7) 28 80 M C Survived—Steroids given, recovered
within 2 months
United States* Cellulitis (12) 34 59 M C Death—Liver related, died on day 10
Note. C = Caucasian NA = Not available.
*Current report Delay = Days from completing amoxicillin/clavulanate to presentation.
drug reactions have a poor prognosis as a group indepen-
dent of the suspect agent or subject age with only a 20%
likelihood of spontaneous survival (7). Therefore, when
clinicians encounter a patient with severe drug induced
liver injury that meets criteria for ALF, they should have
a low threshold for transferring the patient to a transplant
center for evaluation early in their course (6, 7).
The mechanism of amoxicillin and amoxi-
cillin/clavulanate hepatotoxicity remains uncertain.
The clavulinic acid component is suspected of being
responsible for the liver injury since rechallenge with
amoxicillin alone is well tolerated while rechallenge
with amoxicillin/clavulanate is not (2). In addition,
clavulanate combined with other B-lactams can also lead
to liver injury (25). The ratio of amoxicillin to clavulanate
varies from 8:1 to 2:1 in different formulations but the
importance of the ratio in determining the frequency and
severity of hepatotoxicity is unknown (26, 27). Recently,
a genetic basis for amoxicillin/ clavulante hepatotoxicity
has been identified with linkage to the human leukocyte
antigen (HLA) haplotype particularly in patients with
immunoallergic and cholestatic features (20, 28). In
patient #2, the serological HLA haplotype was not similar
to those reported to predispose to hepatotoxicity (Data
not shown). Unfortunately, HLA data was not available
from patient #1.
In summary, we present two patients with severe hepa-
totoxicity due to amoxicillin/clavulanate and amoxicillin
that rapidly progressed to life-threatening ALF. Although
the majority of patients with amoxicillin/clavulanate hep-
atotoxicity have an acute self-limited illness, we recom-
mend that all patients with suspected drug induced ALF
be referred to a transplant center for urgent evaluation due
to their low rate of spontaneous survival (7). To facilitate
further research on the clinical, environmental, genetic
and immunological basis of idiosyncratic drug-induced
hepatotoxicity, prospective studies that collect biological
samples from well-characterized patients compared to un-
affected controls is recommended.
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